TY - JOUR
T1 - Increment Antimicrobial Resistance during the COVID-19 Pandemic
T2 - Results from the Invifar Network
AU - López-Jácome, Luis Esaú
AU - Fernández-Rodríguez, Diana
AU - Franco-Cendejas, Rafael
AU - Camacho-Ortiz, Adrián
AU - Morfin-Otero, María Del Rayo
AU - Rodríguez-Noriega, Eduardo
AU - Ponce-De-León, Alfredo
AU - Ortiz-Brizuela, Edgar
AU - Rojas-Larios, Fabian
AU - Velázquez-Acosta, María Del Consuelo
AU - Mena-Ramírez, Juan Pablo
AU - Rodríguez-Zulueta, Patricia
AU - Bolado-Martínez, Enrique
AU - Quintanilla-Cazares, Luis Javier
AU - Avilés-Benítez, Laura Karina
AU - Consuelo-Munoz, Scarlett
AU - Choy-Chang, Elena Victoria
AU - Feliciano-Guzmán, José Manuel
AU - Couoh-May, Carlos Antonio
AU - López-Gutiérrez, Eduardo
AU - Molina-Jaimes, Aarón
AU - Rincón-Zuno, Joaquín
AU - Gil-Veloz, Mariana
AU - Alcaraz-Espejel, Margarita
AU - Corte-Rojas, Reyna Edith
AU - Gómez-Espinosa, Josué
AU - Monroy-Colin, Víctor Antonio
AU - Morales-De-La-Peña, Cecilia Teresita
AU - Aguirre-Burciaga, Efrén
AU - López-Moreno, Laura Isabel
AU - Martínez-Villarreal, Rebeca Thelma
AU - Cetina-Umaña, Carlos Miguel
AU - Galindo-Méndez, Mario
AU - Soto-Nieto, Gabriel Israel
AU - Cobos-Canul, Dulce Isabel
AU - Moreno-Méndez, Martha Irene
AU - Tello-Gómez, Esmeralda
AU - Romero-Romero, Daniel
AU - Quintana-Ponce, Sandra
AU - Peralta-Catalán, Raúl
AU - Valadez-Quiroz, Alejandro
AU - Molina-Chavarría, Alejandro
AU - Padilla-Ibarra, Cecilia
AU - Barroso-Herrera-Y-Cairo, Irma Elena
AU - Duarte-Miranda, Lizbeth Soraya
AU - López-López, Dulce María
AU - Escalante-Armenta, Samuel Pavel
AU - Osorio-Guzmán, Mónica Jazmín
AU - López-García, Maribel
AU - Garza-Ramos, Ulises
AU - Delgado-Enciso, Iván
AU - Garza-González, Elvira
N1 - Publisher Copyright:
© Copyright 2022, Mary Ann Liebert, Inc., publishers 2022.
PY - 2022/3
Y1 - 2022/3
N2 - Aim: This study aims to assess the changes in antimicrobial resistance among some critical and high-priority microorganisms collected previously and during the coronavirus disease 2019 (COVID-19) pandemic in Mexico. Methods: We collected antimicrobial susceptibility data for critical and high-priority microorganisms from blood, urine, respiratory samples, and from all specimens, in which the pathogen may be considered a causative agent. Data were stratified and compared for two periods: 2019 versus 2020 and second semester 2019 (prepandemic) versus the second semester 2020 (pandemic). Results: In the analysis of second semester 2019 versus the second semester 2020, in blood samples, increased resistance to oxacillin (15.2% vs. 36.9%), erythromycin (25.7% vs. 42.8%), and clindamycin (24.8% vs. 43.3%) (p ≤ 0.01) was detected for Staphylococcus aureus, to imipenem (13% vs. 23.4%) and meropenem (11.2% vs. 21.4) (p ≤ 0.01), for Klebsiella pneumoniae. In all specimens, increased ampicillin and tetracycline resistance was detected for Enterococcus faecium (p ≤ 0.01). In cefepime, meropenem, levofloxacin, and gentamicin (p ≤ 0.01), resistance was detected for Escherichia coli; and in piperacillin-Tazobactam, cefepime, imipenem, meropenem, ciprofloxacin, levofloxacin, and gentamicin (p ≤ 0.01), resistance was detected for Pseudomonas aeruginosa. Conclusion: Antimicrobial resistance increased in Mexico during the COVID-19 pandemic. The increase in oxacillin resistance for S. aureus and carbapenem resistance for K. pneumoniae recovered from blood specimens deserves special attention. In addition, an increase in erythromycin resistance in S. aureus was detected, which may be associated with high azithromycin use. In general, for Acinetobacter baumannii and P. aeruginosa, increasing resistance rates were detected.
AB - Aim: This study aims to assess the changes in antimicrobial resistance among some critical and high-priority microorganisms collected previously and during the coronavirus disease 2019 (COVID-19) pandemic in Mexico. Methods: We collected antimicrobial susceptibility data for critical and high-priority microorganisms from blood, urine, respiratory samples, and from all specimens, in which the pathogen may be considered a causative agent. Data were stratified and compared for two periods: 2019 versus 2020 and second semester 2019 (prepandemic) versus the second semester 2020 (pandemic). Results: In the analysis of second semester 2019 versus the second semester 2020, in blood samples, increased resistance to oxacillin (15.2% vs. 36.9%), erythromycin (25.7% vs. 42.8%), and clindamycin (24.8% vs. 43.3%) (p ≤ 0.01) was detected for Staphylococcus aureus, to imipenem (13% vs. 23.4%) and meropenem (11.2% vs. 21.4) (p ≤ 0.01), for Klebsiella pneumoniae. In all specimens, increased ampicillin and tetracycline resistance was detected for Enterococcus faecium (p ≤ 0.01). In cefepime, meropenem, levofloxacin, and gentamicin (p ≤ 0.01), resistance was detected for Escherichia coli; and in piperacillin-Tazobactam, cefepime, imipenem, meropenem, ciprofloxacin, levofloxacin, and gentamicin (p ≤ 0.01), resistance was detected for Pseudomonas aeruginosa. Conclusion: Antimicrobial resistance increased in Mexico during the COVID-19 pandemic. The increase in oxacillin resistance for S. aureus and carbapenem resistance for K. pneumoniae recovered from blood specimens deserves special attention. In addition, an increase in erythromycin resistance in S. aureus was detected, which may be associated with high azithromycin use. In general, for Acinetobacter baumannii and P. aeruginosa, increasing resistance rates were detected.
KW - Acinetobacter baumannii complex
KW - Antimicrobial resistance
KW - COVID-19 pandemic
KW - Enterobacter cloacae
KW - Enterococcus faecium
KW - Escherichia coli
KW - INVIFAR
KW - Klebsiella pneumoniae
KW - Pseudomonas aeruginosa
KW - Staphylococcus aureus
UR - http://www.scopus.com/inward/record.url?scp=85125883160&partnerID=8YFLogxK
U2 - 10.1089/mdr.2021.0231
DO - 10.1089/mdr.2021.0231
M3 - Artículo
C2 - 34870473
AN - SCOPUS:85125883160
SN - 1076-6294
VL - 28
SP - 338
EP - 345
JO - Microbial drug resistance (Larchmont, N.Y.)
JF - Microbial drug resistance (Larchmont, N.Y.)
IS - 3
ER -